Phase II/ Phase III

Bellerophon Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal

Lead Product(s): Nitric Oxide

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The results from this first cohort established the safety of the iNO30 dose and confirmed the potential for INOpulse to provide clinically meaningful benefits in levels of daily activity in this patient population.

SGS Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients

Lead Product(s): Sarconeos

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Biophytis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 08, 2020

Details:

French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.

Biophytis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement

Lead Product(s): Sarconeos

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co., LLC

Deal Size: $6.8 million Upfront Cash: Undisclosed

Deal Type: Private Placement July 03, 2020

Details:

Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associated with COVID-19.

Relief Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

Lead Product(s): Aviptadil

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2020

Details:

The multicenter clinical trial will enroll patients with COVID-19 and respiratory failure in the hopes that RLF-100 can decrease mortality in this condition and help to improve the ability of the patient’s lungs to transfer oxygen to the body.

Relief Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Relief Therapeutics and NeuroRx Enrolls First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 ARDS

Lead Product(s): Aviptadil

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: NeuroRx

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100. RLF-100 is a patented formulation of Aviptadil, which binds to alveolar type 2 cells in the lungs inhibiting pro-inflammatory cytokines.

Mesoblast

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS

Lead Product(s): Remestemcel-L

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $90.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 13, 2020

Details:

A significant portion of the net proceeds will be used to scale-up manufacturing of remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19 ARDS.

Athersys

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study

Lead Product(s): MultiStem Cell Therapy

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

First patients have been enrolled in Athersys’ pivotal Phase 2/3 study entitled, MultiStem® Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Bellerophon Therapeutics

Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal

SGS Life Sciences

Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients

Biophytis

Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement

Relief Therapeutics

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

Relief Therapeutics

Relief Therapeutics and NeuroRx Enrolls First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 ARDS

Mesoblast

Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS

Athersys

Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study